Gene Expression in MS Patients Before and During Treatment With Interferon-beta
Gene Expression in MS Patients Before and During Treatment With Interferon-beta
Clinical and experimental evidences suggest that there is a variability in therapeutic
 response to immunomodulating therapies in Multiple Sclerosis patients.

 Microarrays is a technology that permits to monitor the expression levels of thousands of
 genes at a time.

 The specific aim of this study is to identify predictive factors of therapeutic response in
 MS patients treated with high-dose Interferon-Beta.
Inclusion Criteria:

 -  diagnosis of relapsing-remitting MS (McDonald criteria)

 -  age between 18-55

 -  EDSS less or equal to 5.5

 Exclusion Criteria:

 -  use of any other disease modifying drugs

 -  use of corticosteroids during 3 months before starting protocol

 -  clinical relapse during 1 month before starting protocol

 -  serious heart, renal, hepatic or haematological dysfunction defined by laboratory
 exams